<DOC>
	<DOC>NCT01573949</DOC>
	<brief_summary>The Ahmanson-UCLA Cardiomyopathy Center is conducting a clinical research study that will assess the use of the medication metformin to improve quality of life, exercise capacity, and improved outcomes in heart failure patients with pre-DM or early DM (type II). If the patient participates in this study, the patient will receive the drug metformin for approximately 3 months. During the study the patient will undergo comprehensive testing which includes blood draws and echocardiograms. The patient will also fill out a questionnaire. The patient must be 18 years old to participate.</brief_summary>
	<brief_title>A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>symptomatic HF of any etiology age ≥ 18 years fasting blood sugar equal or greater than 100 mg/dL, or preDM (HbA1c 5.7 6.4%) or early DM (HbA1c ≥ 6.5%) current metformin therapy or other antidiabetic therapy previous intolerance to metformin therapy renal dysfunction (Cr &gt;1.5 in men or &gt; 1.4 in women or creatinine clearance &lt; 60 ml/minute) history of lactic acidosis current or planned pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Pre-diabetes</keyword>
	<keyword>Early type II diabetes</keyword>
	<keyword>Metformin</keyword>
	<keyword>Pharmacotherapy with metformin for prevention of DM in HF patients with pre-diabetes (pre-DM) and glycemic control in HF patients with early type II DM</keyword>
</DOC>